TOP > 外国特許検索 > CANCER THERAPEUTIC DRUG AND CANCER TREATMENT METHOD

CANCER THERAPEUTIC DRUG AND CANCER TREATMENT METHOD UPDATE

外国特許コード F170008955
整理番号 (S2015-1669-N0)
掲載日 2017年2月16日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2016JP066393
国際公開番号 WO 2016208348
国際出願日 平成28年6月2日(2016.6.2)
国際公開日 平成28年12月29日(2016.12.29)
優先権データ
  • 特願2015-128139 (2015.6.25) JP
発明の名称 (英語) CANCER THERAPEUTIC DRUG AND CANCER TREATMENT METHOD UPDATE
発明の概要(英語) [Problem] To clarify the role of stem cell regulation factors, including Matrin-3, in cancer showing neural differentiation such as small cell cancer in the lung, and to develop a drug or the like which is useful for the treatment of cancer with relying on the role.
[Solution] In some types of cancer which show a differentiation ability among various types of cancer which have a cancer stem cell regulation mechanism, both a stem cell-maintaining factor and a stem cell differentiation-accelerating factor are expressed at higher levels compared with normal cells and these factors keep a specific balance therebetween. In undifferentiated types of cancer among the above-mentioned various types of cancer, a stem cell-maintaining factor is expressed at a higher level compared with normal cells and these factors keep a specific balance therebetween. In some types of cancer in which the cancer stem cell regulation mechanism is present, there is a specific balance between these stem cell-regulating factors which is different from that in normal cells. In a cancer therapeutic drug and a cancer treatment method according to the present invention, the balance between the above-menioned stem cell-regulating factors is broken down to inhibit the proliferation ability of cancer.
従来技術、競合技術の概要(英語) BACKGROUND ART
Is small cell lung cancer, compared to the other of the cancer cell and the small sizes of the cells, so named. Is characterized by a small cell lung cancer, lung cancer progress faster in the thin, poorly differentiated in rapidly proliferating. Therefore, small cell lung cancer, early stage of the transition to the lymph node or other organ seen, in most cases, can be found in the state of advanced cancer. As a result, the small cell lung cancer, compared to other cancers, are known to have a high mortality rate.
The current, for treatment of small cell lung cancer, anticancer radiation treatment is being performed. However, these treatments are, in an extension of the life expectancy contributes, in a complete cure is extremely difficult at present. In small cell lung cancer, early detection of small cell lung cancer, suppression of growth of the tumor, if it is possible to suppress metastasis, the treatment result is believed to improve dramatically. However, the molecular basis of small cell lung cancer often will be an as-yet point, higher therapeutic effect can be expected in the present situation there is no effective therapy is.
Having such a feature is small cell lung cancer, is further characterized, which is known to show neuronal differentiation. Neural differentiation and, to maintain the stem cell is a stem cell factors, into cells of the nervous system phenomenon. The manner in which the neural differentiation in controlled studies have been conducted on the at least one but, not clearly. In addition, the neuronal differentiation, small cell lung cancer is determined to be associated with the condition does not become apparent, of course, not connected to the development of a therapeutic agent.
On the other hand, is Matrin-3, recently, an important finding can be reported THs, attention has been paid molecule. Matrin-3 is nuclear protein which 125-kDa (non-patent document 1, non-patent document 2), chromatin organisation, DNA replication, RNA processing have functions such as (non-patent document 3) are known. Matrin-3 is, up to now, most of the analyzed Neuroscience field was found to be not taken. However, recently Matrin-3 gene mutations on the grounds that the familial amyotrophic lateral sclerosis (non-patent document 4), the network Matrin-3, homeodomain transcriptional program to be essential for the (non-patent document 5) and the like have been reported.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY
  • 発明者(英語)
  • NIIMORI KANAKO
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KN KP KR KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
ライセンスをご希望の方、特許の内容に興味を持たれた方は、下記「問合せ先」まで直接ご連絡ください。

PAGE TOP

close
close
close
close
close
close